One Two
You are here: Home News

News

Bayer PhD-Thesis Prize award & BIGS-DrugS Kick-off Meeting

11th July.2022: After two years of exclusively virtual meetings, the PhD-Thesis prizes were awarded this year in a face-to-face event . At the same time the postponed BIGS-DrugS Kick-off Meeting could finally take place. Both events took place as a combined event. After the scientific lecture program, a great party was celebrated in bright weather. For further details & fotos please have a look at the German homepage of PZB - Aktuelles

Nature-Publikation from PZB-Speaker Prof. Dr. A. Pfeifer

5th July 2022: Apoptotic brown adipocytes enhance energy expenditure via extracellular inosine

Brown adipose tissue (BAT) dissipates energy and promotes cardio-metabolic health. In this publication, Nieman et al. identifiy inosine as novel tissue-messenger in brown fat (BAT). They show that treatment of mice with inosine increased BAT-dependent energy expenditure and induced “browning” of white adipose tissue. This work is funded by the DFG.

Nature Pfeifer.png

(c) Michelle Y. Jaeckstein and Jörg Heeren, University Medical Center, Hamburg-Eppendorf, Hamburg, Germany

 

The Bonner Newspaper Der General-Anzeiger wrote about research of PZB member Prof. Christa E. Müller at the Pharmaceutical Institut, pharmaceutical & medicinal Chemistry University of Bonn

16th May 2022: Schlafmittel für Killerzellen enttarnt. Pharmazeuten der Uni Bonn haben einen Rezeptor entschlüsselt, mit dem Krebszellen die Immunabwehr lahmlegen

For the hole article pleas see the german homepage

Link to the publication in the journal Angewandte Chemie

 

New Collaborative Research Center for PZB member and speaker Prof. Dr. Alexander Pfeifer

25th November 2021: In the Transregional SFB 333 "Brown and beige fat - organ interactions, signalling pathways and energy balance (BATenergy)", teams are looking at different types of adipose tissue and their role in metabolic diseases. The network is a consortium of the Universities of Bonn and the University Hospital Bonn, the University Hospital Hamburg-Eppendorf (UKE), the Technical University of Munich (TUM) and the Helmholtz Center Munich. Spokesman is  Prof. Dr. Alexander Pfeifer.

Link to the news

Photo Prof. Pfeifer.png

Prof. Dr. Alexander Pfeifer

 Bayer Thesis Prize 2020

25th October 2021: As in previous years, Bayer AG, in cooperation with the Pharma Centre Bonn and the Limes Institute, again awarded three prizes  for outstanding doctorates in the field of pharmaceutical research. The arwardees are the former BIGS DrugS PhD students:

  • Dr. Xia Lia - Application of population, physiolgically based, and semi-physiolgical pharmacokinetic modeling to assess sources of pharmacokinetic variability in individual drugs (workung group Prof. Fuhr)
  • Dr. Christian Steinebach - Design and Synthesis of Molecular Chimeras for Induced degradation of Tumor-associated Proteins (working group Prof. Gütschow )
  • Dr. Sneha Singh - Structural and Functional characterization of Human coagulation Factor XII (working group Prof. Oldenburg)

Congratulation!

Bild1.png

Christian.png

Sneha.png

Xia.png

 New members in the Pharma Center

24th September 2021: Prof. Dr. Finn Hansen was accepted as new member of the PharmaCenter Bonn. Congratulation!

 

VW Foundations supports Corona research by PZB members

 

30th of June 2021: Prof. Christa E. Müller and Prof. Michael Gütschow (both pharm. & med. chemistry, Institute of Pharmacy) receive up to 500,000 euros over three years from the VW Foundation to support their corona research. The two scientists are researching drugs against SARS-CoV-2 and other coronaviruses. The drug target structure is the main protease of the corona viruses. A great advantage of this target structure is that practically no mutations are known. With the money, the team can continue the research that has so far been financed from their own funds. For example, studies on pharmacokinetics and toxicity will be carried out and important drug compounds will be optimised. We wish both scientists and their team every success in their research!

Link to the news

 

 

Prof. Dr. Christa E. Müller to lead ACS Pharmacology & Translational Sciences

 

3th of April 2021: Prof. Christa E. Müller, Speaker of PZB, Pharmaceutical Institut (Pharm. & med. Chemistry) has been named editor in chief of ACS Pharmacology & Translational Science. The peer-reviewed journal, launched by the American Chemical Society in 2018, highlights research across the biological sciences. Here the interviewon the occasion of her nomination:

Why did you want to be Editor-in-Chief of ACS Pharmacology & Translational Science?

ACS is the world’s largest scientific society and a true global leader in chemistry-based science. Being appointed the EIC of a journal published by ACS is exactly what I have been waiting for! I am passionate about this emerging journal, its role in publishing cutting-edge pharmacological research, and its mission to bridge the gap with translational science. This role provides me with a wonderful opportunity to give back to the community and to use my qualities as a leader, including my energy and creativity, to design, direct, and shape the future of this young, promising journal.

What are your goals for the journal over the coming year?

My goals for the coming year are to make the journal widely known and highly valued by pharmacologists, medicinal chemists, and translational scientists in general. I want it to become one of the leading journals in the field with a great reputation and an Imin the first quartile of pharmacology journals. I plan to launch new initiatives, including highlights and a Review article series on “Recommended Pharmacological Tool Compounds,” among others. The journal will set new standards in the field, support diversity, and emerging young scientists will play an active role. I believe passionately in the success of ACS Pharmacology & Translational Science and its impact on people.

Why should people doing work in the field submit their next manuscript to ACS Pharmacology & Translational Science?

This journal covers a broad range of topics, encompassing biology, pharmacology, and chemistry. Here are five reasons to publish in ACS Pharmacology & Translational Science:

  1. High-impact articles featuring a wide variety of subjects
  2. High scientific and ethical standards
  3. Flexibility in formatting
  4. Rapid time to publication
  5. No charges or fees to submit a manuscript or publish an article under the traditional subscription model (non-open access)

What are you and your group working on now?

Last year, we started working in a completely new field: Developing therapeutic drugs for treating coronavirus infections such as COVID-19. Our main, longstanding interest is in targets involved in purinergic signaling, including purine receptors and ectonucleotidases, which play a major role in inflammation, immunity, and cancer. Moreover, we are interested in orphan GPCRs and G proteins as drug targets. My group is relatively large, highly interdisciplinary, and our techniques include synthetic organic chemistry, analytical biochemistry, molecular and structural biology, and pharmacology.

What advice would you give to the field’s early career scientists?

Look for mentors, build your network, be open and always talk to people, collaborate with great scientists, and enjoy your work. You should listen to criticism (if it’s justified) and try to improve. Lastly, find a balance between your work and private life.

When you aren’t doing research and fulfilling your editorial duties, how do you spend your time?

I have many interests and hobbies, but unfortunately, not enough time to pursue all of them. I love reading, writing, sports, cooking, and traveling. One of my great passions is dancing: Tango Argentino, salsa, zouk, and more.

 

 

Link to the news

 

BIGS DrugS researcher discover SARS-CoV-2 inhibitors

5th of March 2021: BIGS DrugS members Prof. Christa E. Müller and Prof. Michael Gütschow (both Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, )  and their research groups developed two classes of compounds which are able block the main protease of SARS-CoV-2. Blocking these protease can inhibit replication of the SARS-CoV-2 corona virus. These rationally designed inhibitors are promising candidates for further development. The ultimate goal ist to attaining antiviral drugs against COVID-19.The results were published in the journal "Angewandte Chemie". Targeting the Main Protease of SARS-CoV-2: From th Establishment of High Throughput Screening to the Design of Tailored Inhibitors. Congratulations and good luck for the further research!

Link to the press office of the University of Bonn

Award Bayer AG PhD Thesis Prize 2019

15th of September 2020: The prizes awarded by Bayer AG in cooperation with the Pharma Center Bonn and the Limes Institute for three outstanding doctoral PhD theses in the field of pharmaceutical research were awarded to three excelent young scientists. The merited winners are Dr. Lorenz Marc Michael Fülle, PhD (working group Prof. Irmgard Förster), Dr. Franzisak Ersoy, PhD (working group Prof. Günter Wagner) and Dr. Esther Sophia Bochmann, PhD (working group Prof. Karl G. Wagner). Due to the Corona Pandemic the awardees, their supervisor, Dr. Nils Burkardt, PhD, and Dr. Heidrun Dorsch, PhD met virtual and Dr. Burkhardt awarded the prizes each worth 1500 euros

Promotionspreis 2019.png

Argelander grants for corona research for BIGS DrugS PhD studens

3th of July 2020: Four BIGS-DrugS PhD students from working groups of PZB members receive financial support from the University of Bonn's special research call. This special call supports research to the Covid 19 Pandemic.
Marie Thérèse Hopp, PhD student in the working group group of PZB member Prof. Dr. Diana Imhof (Pharmaceutical Biochemistry & Bioanalytics) studies in her project the role of the blood component heme in COVID-19 infections. The aim is, to develop better diagnotics and treatment of present or occuring hemolytic events. Christian Steinbach PhD student in the working group of PZB member Prof. Dr. Michael Gütschow (Pharmaceutical & Medical Chemistry) and Fabian Baltes and Lukas Gockel both PhD students in the working group of PZB member Prof. Dr. Gerd Bendas (Pharmaceutical & Cell Biological Chemistry) receive funding for their project on the development of novel chimeric drugs. These drugs might be able to slow down the penetration of the sars-CoV-2 virus into the cells and thus inhibit the spread of the virus. The funding amounts to €25000 per project.

We congratulate and to our PhD students and wish them a successful research!

Link to the article

Contact: Marie Thérèse Hopp

              Christian Steinebach, Fabian Baltes, Lukas Gockel

The Pharma Center Bonn (PZB) is member of the Academic Drug Discovery Consortium. 

11th of May 2020: This consortium is  a professinonal society dedicatede to building the community of academic drug discovery lab and the companies, universities and goverment agenties that support and partners with these centers.

Academic DRUG DISCOVERY Consortium

Four new members in the Pharma Center

27th February 2020: Prof. Dr. Britta Hänisch, Prof. Dr. Werner Knöss, Prof. Dr. Philipp Sasse, Prof. Dr. Günther Weindl were accepted as new members of the PharmaCenter Bonn. Congratulation!

Activation of opioid receptor detected

27th of November 2019: PhD student Tobias Claff from working group of PZB Chair Prof. Dr. Christa E. Müller in collaboration with research collegues from Shangai, Brussels, Canada and USA was showed by using X-ray crystallography  which parts of the receptor are resonsible for binding the active ingredienst. It should be possible to develop targets that activate  exclusively DOP. Link

Award Bayer AG PhD Thesis Prize 2018

21th of October 2019: The prizes awarded by Bayer AG in cooperation with the Pharma Center Bonn and the Limes Institute for three outstanding doctoral PhD Theses in the field of pharmaceutical research were awarded to three excelent young scientists.

Further information are published at the BIGS DrugS Homepage:

Bayer AG PhD Thesis Prize 2018

New "Sonderforschungsbereich" for The Unitersity of Bonn

19th of August 2019: "Cellular mechanisms of antibiotic effect and production" PZB member Prof. Tanja Schneider is co-petitioner

 

Kick-Off Meeting BIGS DrugS Class 2018

15th of February 2019: The Kick-Off Meeting for the Bigs DrugS  Class took place. For more infos please have a look at the BIGS DrugS Homepage

 

New member

19th February 2018: PD Dr. Dr. Marco Weiergräber was accepted as new member of the PharmaCenter Bonn.

 

BIGS DrugS Kick-Off-Meeting and 1. Graduate Symposium 2017

6th December 2017: The BIGS DrugS Kick-Off-Meeting for Class 2017 took place together with the first BIGS DrugS Graduate Symposium on the 6th of December, 2017.

For more information and pictures of the event, visit the BIGS DrugS website:

BIGS DrugS - Kick-Off-Meeting & 1st Graduate Symposium - 06.12.2017

 

New members

26th January 2017: Prof. Dr. Tanja Schneider was accepted as new member of the Pharma Center.

Document Actions